Since the proliferation of cancer cells is related to angiogenesis and tyrosine kinase, anti- vascular endothelial growth factor (VEGF) antibodies such as bevacizumab, anti-vascular endothelial growth factor receptors (VEGFR) antibodies such as ramucirumab, and tyrosine kinase inhibitors such as sunitinib are also approved for TNBC treatment [42,43,44,45,46,47]. This evidence concerns the gene KDR and cancer.